托伐普坦与液体限制治疗低钠血症住院患者的经济分析

数据集获取（Figshare）

• 源站标题：An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia
• DOI：10.6084/m9.figshare.5008370.v1
• 发布日期：2017-05-16
• 文件数：3 个
• 文件总体积：41.35 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/An_economic_analysis_of_tolvaptan_compared_with_fluid_restriction_among_hospitalized_patients_with_hyponatremia/5008370

命令行下载

curl -L -o "Supplementary Table S-1.docx" "https://ndownloader.figshare.com/files/8438639"
curl -L -o "Supplementary Table S-2.docx" "https://ndownloader.figshare.com/files/8438642"
curl -L -o "Supplementary Table S-3.docx" "https://ndownloader.figshare.com/files/8438645"

文件清单

• Supplementary Table S-1.docx（13.61 KB）
• Supplementary Table S-2.docx（13.87 KB）
• Supplementary Table S-3.docx（13.88 KB）

文件总体积 41.35 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Objective: The vasopressin-receptor antagonist tolvaptan is used for the treatment of hyponatremia (HN) in hospitalized patients with congestive heart failure (CHF) or syndrome of inappropriate antidiuretic hormone secretion (SIADH). The objective of this economic modeling study was to assess the potential cost and health outcomes associated with tolvaptan in comparison with fluid restriction (FR).
Methods: A decision-analytic model was developed to estimate potential cost and health outcomes associated with tolvaptan compared with FR among hospitalized CHF and SIADH patients with severe HN (serum sodium [SS] levels Results: Model results suggest that, among hospitalized CHF patients with severe HN, the use of tolvaptan compared with FR may lead to reductions of 7.2% and 4.6% in ICU admissions and 30-day readmissions, respectively. Compared with FR, tolvaptan may result in total cost-savings of $156 per hospitalized CHF patient. Among hospitalized SIADH patients with severe HN, the model suggested reductions of 14.6% and 5.1% in ICU admissions and 30-day readmissions, respectively. Compared with FR, tolvaptan may result in total cost-savings of $135 per hospitalized SIADH patient. PSAs found that the probabilities of net cost-savings from the use of tolvaptan compared with FR were 64% and 59% among patients with severe HN with CHF and SIADH, respectively.
Conclusions: Decision-analytic modeling based on published data for hospitalized CHF and SIADH patients with severe HN, indicates that tolvaptan compared with FR has the potential to improve health outcomes and produce cost-savings that more than offset the cost of tolvaptan.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.5008370.v1（source: https://tandf.figshare.com/articles/dataset/An_economic_analysis_of_tolvaptan_compared_with_fluid_restriction_among_hospitalized_patients_with_hyponatremia/5008370）。